SLNStock Financials & Fundamentals
Company Info
Company Full Name
Silence Therapeutics PLC Sponsored ADR
Full name of the company.
Industry Name
MEDICAL-DRUGS
Industry name
Major Industry Name
DRUGS
Major industry name
Sector Name
Medical
Sector name
Market Info
Current Price
$6.24
Current price of the stock
Trading Volume
$323K
Trading volume of the stock
Market Capitalization
$231.5M
Market capitalization of the company
Market Cap Category
Micro Cap
Category of market capitalization
Long-Term Growth Estimate
-
Long-term growth mean estimate
Analyst Rating Mean
4.14
Mean analyst rating
Potential Upside
441.67%
Potential price appreciation based on analyst price targets
EPS Surprise Percentage Difference
-12.50%
Percentage difference of EPS surprise
Dividends
Dividend Change (1 Year)
-
Dividend change over 1 year
Dividend Rate
$0.00
Shows the amount of dividend paid
Balance Sheet
Total Debt to Equity Ratio
-
Total debt to total equity ratio
Current Ratio
4.62
Current ratio
Company Profitability
Gross Profit Margin
59.34%
Gross profit margin
Operating Profit Margin
-203.47%
Operating profit margin
EBIT Margin
-203.47%
Earnings before interest and taxes (EBIT) margin
EBITDA Margin
-201.50%
Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin
Pretax Profit Margin
-168.35%
Pretax profit margin
Net Profit Margin
-171.37%
Net profit margin
Return on Equity (ROE)
-246.57%
Measures profitability relative to shareholders' equity
Return on Tangible Equity
-465.48%
ROE excluding intangible assets
Return on Assets (ROA)
-45.40%
Measures profitability relative to total assets
Return on Invested Capital (ROIC)
-246.57%
Measures profitability relative to invested capital
Management Effectiveness
Asset Turnover (quarterly)
0.26
Asset turnover ratio
Inventory Turnover (quarterly)
-
Inventory turnover ratio
Receivables Turnover (quarterly)
1.39
Receivables turnover ratio
Days Sales Outstanding
262.21
Average number of days it takes to collect receivables
Valuation Measures
Price-to-Earnings (P/E) Ratio
-4.08
Measures valuation relative to earnings
Forward P/E Ratio
-
P/E based on future earnings estimates
Price-to-Sales (P/S) Ratio
8.76
Measures valuation relative to sales
Price-to-Book (P/B) Ratio
11.24
Measures valuation relative to book value
Price-to-Operating Cash Flow (P/OCF) Ratio
-3.17
Measures valuation relative to operating cash flow
Price-to-Free Cash Flow (P/FCF) Ratio
-3.10
Measures valuation relative to free cash flow
Cash Flow Statement
Net Acquisitions/Divestitures
0
Indicates company's M&A activity
SLNStock Financials & Fundamentals
Company Info
| Parameter | Value | Description |
|---|---|---|
| Company Full Name | Silence Therapeutics PLC Sponsored ADR | Full name of the company. |
| Industry Name | MEDICAL-DRUGS | Industry name |
| Major Industry Name | DRUGS | Major industry name |
| Sector Name | Medical | Sector name |
Market Info
| Parameter | Value | Description |
|---|---|---|
| Current Price | $6.24 | Current price of the stock |
| Trading Volume | $323K | Trading volume of the stock |
| Market Capitalization | $231.5M | Market capitalization of the company |
| Market Cap Category | Micro Cap | Category of market capitalization |
| Long-Term Growth Estimate | - | Long-term growth mean estimate |
| Analyst Rating Mean | 4.14 | Mean analyst rating |
| Potential Upside | 441.67% | Potential price appreciation based on analyst price targets |
| EPS Surprise Percentage Difference | -12.50% | Percentage difference of EPS surprise |
Dividends
| Parameter | Value | Description |
|---|---|---|
| Dividend Change (1 Year) | - | Dividend change over 1 year |
| Dividend Rate | $0.00 | Shows the amount of dividend paid |
Balance Sheet
| Parameter | Value | Description |
|---|---|---|
| Total Debt to Equity Ratio | - | Total debt to total equity ratio |
| Current Ratio | 4.62 | Current ratio |
Company Profitability
| Parameter | Value | Description |
|---|---|---|
| Gross Profit Margin | 59.34% | Gross profit margin |
| Operating Profit Margin | -203.47% | Operating profit margin |
| EBIT Margin | -203.47% | Earnings before interest and taxes (EBIT) margin |
| EBITDA Margin | -201.50% | Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin |
| Pretax Profit Margin | -168.35% | Pretax profit margin |
| Net Profit Margin | -171.37% | Net profit margin |
| Return on Equity (ROE) | -246.57% | Measures profitability relative to shareholders' equity |
| Return on Tangible Equity | -465.48% | ROE excluding intangible assets |
| Return on Assets (ROA) | -45.40% | Measures profitability relative to total assets |
| Return on Invested Capital (ROIC) | -246.57% | Measures profitability relative to invested capital |
Management Effectiveness
| Parameter | Value | Description |
|---|---|---|
| Asset Turnover (quarterly) | 0.26 | Asset turnover ratio |
| Inventory Turnover (quarterly) | - | Inventory turnover ratio |
| Receivables Turnover (quarterly) | 1.39 | Receivables turnover ratio |
| Days Sales Outstanding | 262.21 | Average number of days it takes to collect receivables |
Valuation Measures
| Parameter | Value | Description |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -4.08 | Measures valuation relative to earnings |
| Forward P/E Ratio | - | P/E based on future earnings estimates |
| Price-to-Sales (P/S) Ratio | 8.76 | Measures valuation relative to sales |
| Price-to-Book (P/B) Ratio | 11.24 | Measures valuation relative to book value |
| Price-to-Operating Cash Flow (P/OCF) Ratio | -3.17 | Measures valuation relative to operating cash flow |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.10 | Measures valuation relative to free cash flow |
Cash Flow Statement
| Parameter | Value | Description |
|---|---|---|
| Net Acquisitions/Divestitures | 0 | Indicates company's M&A activity |